At Genetducts, we are dedicated to transforming Breast Healthcare through advanced proteomic insights. Genetducts has a unique precision medicine test for women (HALO), for the evolutionary advancement in helping identify targeted biomarkers associated with breast cancer development thus offering the earliest detection of breast cancer possible and maximizing the lives saved.
CYductDX is developing clinical products for the identification, diagnosis and treatment of early breast disease as well as cancerous and pre-cancerous lesions within the mammary ducts. The foundational premise of CYductDX as a breast care company is predicated on scientific research that has proven that changes in epithelia cells of the mammary ducts and subsequent breast ductal fluid composition are reflective of breast health and breast disease.